全文获取类型
| 收费全文 | 274篇 |
| 免费 | 88篇 |
| 国内免费 | 2篇 |
专业分类
| 儿科学 | 2篇 |
| 妇产科学 | 1篇 |
| 基础医学 | 33篇 |
| 口腔科学 | 9篇 |
| 临床医学 | 17篇 |
| 内科学 | 200篇 |
| 皮肤病学 | 4篇 |
| 神经病学 | 7篇 |
| 特种医学 | 1篇 |
| 外科学 | 10篇 |
| 综合类 | 6篇 |
| 预防医学 | 5篇 |
| 药学 | 61篇 |
| 中国医学 | 1篇 |
| 肿瘤学 | 7篇 |
出版年
| 2024年 | 3篇 |
| 2023年 | 7篇 |
| 2022年 | 8篇 |
| 2021年 | 13篇 |
| 2020年 | 10篇 |
| 2019年 | 15篇 |
| 2018年 | 39篇 |
| 2017年 | 36篇 |
| 2016年 | 24篇 |
| 2015年 | 10篇 |
| 2014年 | 39篇 |
| 2013年 | 28篇 |
| 2012年 | 26篇 |
| 2011年 | 34篇 |
| 2010年 | 18篇 |
| 2009年 | 12篇 |
| 2008年 | 7篇 |
| 2007年 | 3篇 |
| 2006年 | 6篇 |
| 2005年 | 5篇 |
| 2004年 | 4篇 |
| 2003年 | 3篇 |
| 2002年 | 2篇 |
| 2001年 | 1篇 |
| 2000年 | 3篇 |
| 1999年 | 1篇 |
| 1998年 | 3篇 |
| 1997年 | 1篇 |
| 1996年 | 1篇 |
| 1995年 | 1篇 |
| 1992年 | 1篇 |
排序方式： 共有364条查询结果，搜索用时 31 毫秒
1.
Humayun Sharif L. Robert Hollingsworth Andrew R. Griswold Jeffrey C. Hsiao Qinghui Wang Daniel A. Bachovchin Hao Wu 《Immunity》2021,54(7):1392-1404.e10
- Download : Download high-res image (167KB)
- Download : Download full-size image
2.
3.
4.
《Archives of Cardiovascular Diseases》2021,114(11):748-760
- Download : Download high-res image (140KB)
- Download : Download full-size image
5.
Y.K. Cho Y.M. Kang S.E. Lee J. Lee J.-Y. Park W.J. Lee Y.-J. Kim C.H. Jung 《Diabetes & metabolism》2018,44(5):393-401
Background
This review evaluated the efficacy and safety of a combination therapy comprising a sodium-glucose cotransporter type 2 inhibitor (SGLT2i) and dipeptidyl peptidase-4 inhibitor (DPP4i) in type 2 diabetes.Methods
A literature search through to May 2017 was carried out of PubMed, Embase and the Cochrane Central Register of Controlled Trials. Studies were eligible if they were randomized controlled trials (RCTs) comparing SGLT2i plus DPP4i (SGLT2i/DPP4i) against DPP4i ± placebo or SGLT2i ± placebo and published in English. The primary outcome was change in HbA1c from baseline.Results
Eight RCTs comparing SGLT2i/DPP4i and DPP4i, and five RCTs comparing SGLT2i/DPP4i and SGLT2i, with three RCTs involving both comparisons, were included in the present review. SGLT2i/DPP4i resulted in a greater mean HbA1c reduction [weighted mean difference (WMD]): ?0.62%] than did DPP4i alone, which was a much less marked reduction (WMD: ?0.35%) than with SGLT2i alone. Also, significant differences in body weight loss from baseline were observed only with SGLT2i/DPP4i vs. DPP4i, but not vs. SGLT2i. The risk of hypoglycaemic events was low and similar between treatment groups. When subjects were stratified based on baseline HbA1c, any reduction by SGLT2i/DPP4i in relation to DPP4i was proportional to baseline HbA1c levels. However, compared with SGLT2i, HbA1c reductions with SGLT2i/DPP4i were modest regardless of baseline HbA1c.Conclusion
Combination therapy with SGLT2i and DPP4i is both efficacious and safe. In particular, a marked additional glucose-lowering effect is evident when SGLT2i is combined with or added to DPP4i, and not vice versa. However, baseline HbA1c determined the additional glucose-lowering effects of SGLT2i in combined treatment with DPP4i. 相似文献6.
Chia-Lin Lee Wayne Huey-Herng Sheu I-Te Lee Shih-Yi Lin Wen-Miin Liang Jun-Sing Wang Yu-Fen Li 《Diabetes & metabolism》2018,44(2):121-128
Aim
To investigate the effect of changes in fasting plasma glucose (FPG) variability, as assessed by 2-year trajectories of FPG variability, on mortality risk in patients with type 2 diabetes (T2D).Methods
From 2009 to 2012, outpatients with T2D, aged > 18 years, were enrolled from a medical centre. FPG was measured every 3 months for 2 years in 3569 people. For each of the eight 3-month intervals, FPG variability and means were calculated, with variability defined as the coefficient of variation of FPG. Also, trajectories of FPG variability and means were determined separately, using group-based trajectory analysis with latent class growth models. These models were fitted using the SAS Proc Traj procedure. The primary outcome was all-cause mortality, which was followed-up to the end of 2014.Results
Five distinct trajectories of FPG variability (low, increasing, fluctuating, decreasing and high) and means (well controlled, stable control, worsening control, improving control and poor control) were established. The five trajectories of mean FPG were all associated with the same mortality risk. In contrast, in comparison to the low FPG variability trajectory, the fluctuating, decreasing and high variability trajectories all had significantly higher risks of mortality, with respective hazards ratios of 2.63 (95% CI: 1.40–4.93; P = 0.003), 2.78 (95% CI: 1.33–5.80; P = 0.007) and 4.44 (95% CI: 1.78–11.06; P = 0.001) after multivariable adjustment.Conclusion
Changes in FPG variability were independently associated with increased mortality risk in patients with T2D. 相似文献7.
8.
9.
10.
Gamze Argun-Kurum Fatma Kaya-Dagistanli Melek Ozturk 《Pharmacological reports : PR》2019,71(4):721-731
BackgroundWe aim to investigate the effects of dipeptidyl-peptidase-4 inhibitor (Vildagliptin-VG) on DDR-1 as a marker for endocrine progenitor cells, β-cell regeneration, and apoptosis in neonatal streptozotocin (n2-STZ) diabetics.MethodsNeonatal rats were divided into two main groups as short- and long-term treatment, each consisted of four groups; (1) Control, (2) n2-STZ diabetic (single dose of 100 mg/kg STZ at 2nd day of birth), (3) n2-STZ + VG (60 mg/kg/day VG orally; for 8 and 28 days), (4) VG (60 mg/kg/day orally; for 8 and 28 days). Blood glucose levels and body weights were measured, and the tissue sections were immunostained using insulin, glucagon, somatostatin, PCNA, Pdx-1 and DDR-1 antibodies. The TUNEL method was used for apoptosis.ResultsThe number of β cells in islets of the n2-STZ + VG group increased compared to the n2-STZ group; insulin (+) cells were observed individually or as small clusters in exocrine tissue, between pancreatic duct epithelial cells, and around the ducts. The number of Pdx-1 and DDR-1 positive cells in islet and extra-islet pancreas tissue was elevated as a result of VG application compared to the STZ diabetic group; the number of double positive cells for DDR-1 and insulin increased in n2-STZ + VG rats.ConclusionWe showed that vildagliptin promotes β cell neogenesis and regeneration, stimulates DDR-1 expression as an endocrine cell progenitor marker, suppresses apoptosis, induces islet cell proliferation and rearranges islet morphology in the n2-STZ diabetes model. 相似文献